CLL1+CD33 CAR-T(Zhejiang University)

N/A

Report date: 2022/07/22 20:00:33

Base Information

Drug NameCLL1+CD33 CAR-T(Zhejiang University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAnti-C-Type lectin domain family 12 member AAnti-Myeloid cell surface antigen CD33

TargetsC-Type lectin domain family 12 member AMyeloid cell surface antigen CD33

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesZhejiang University

China Registration ClassN/A

Develop Information

Active CompaniesZhejiang University

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A